Feinstein Institutes Appoints Cancer Research Leader to Strengthen Oncology Focus
Event summary
- Dr. Tobias Janowitz appointed director of the Institute of Cancer Research at Feinstein Institutes, effective August 31, 2026.
- Janowitz will also lead translational cancer research at Northwell Health’s Cancer Institute while maintaining his role at Cold Spring Harbor Laboratory.
- Feinstein Institutes aims to leverage Janowitz’s expertise in cancer metabolism and immune response to advance treatment options.
- Northwell Health’s 2025 launch of the START New York-Long Island facility underscores its commitment to early-phase cancer clinical trials.
The big picture
The appointment of Dr. Tobias Janowitz reflects Feinstein Institutes’ push to strengthen its oncology research capabilities amid growing competition in precision medicine. Northwell Health’s investment in early-phase clinical trials positions it as a key player in decentralized cancer care, aligning with broader industry trends toward community-based research.
What we're watching
- Research Synergy
- How the integration of Cold Spring Harbor Laboratory’s research with Feinstein Institutes’ resources will accelerate cancer treatment breakthroughs.
- Clinical Trial Expansion
- Whether Northwell Health’s START facility can sustain rapid enrollment and trial completion rates under Janowitz’s leadership.
- Talent Attraction
- The pace at which Feinstein Institutes can recruit additional top-tier cancer researchers following Janowitz’s appointment.
Related topics